Strategic Partnerships RAND: INBRAIN has active partnerships with Microsoft and Kyndryl to advance AI-driven neural interfaces and BCI therapies, signaling a strong alignment with enterprise tech providers that can amplify go-to-market reach and systems integration opportunities.

Global Expansion RAND: The company is expanding to Boston and the U.S. West Coast while maintaining a Barcelona HQ, creating multiple regional touchpoints for sales cycles, local partnerships, and clinical/academic collaborations that can accelerate customer proximity and deployment.

FDA Recognition RAND: FDA Breakthrough Designation enhances credibility and title risk mitigation for buyers; leverage this to reduce customer risk and accelerate procurement, especially in hospital networks and neurology centers evaluating BCI therapies.

Funding Strength RAND: With substantial funding and a revenue range in the low to mid millions, there is capacity to support pilot programs, co-development deals, and expansion initiatives with strategic customers who require robust feasibility studies.

AI and Graphene Advantage RAND: Focus on graphene-based high-density neural interfaces and AI-driven therapies positions INBRAIN at the intersection of advanced materials and software, offering cross-sell opportunities with hardware-intensive medical device buyers and AI-enabled healthcare platforms.